ArticleBiomedical reports2025
Short-term cognitive effects of anticholinergics in patients with neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurogenic lower urinary tract dysfunction (NLUTD) is common in individuals with neurological disorders, leading to bladder overactivity and incontinence. Anticholinergic medications are frequently prescribed for symptom control, but concerns exist regarding potential cognitive impairments. The present systematic review and meta-analysis aimed to evaluate the short-term cognitive effects of anticholinergics in patients with NLUTD. PubMed, Embase, Cochrane Library and Scopus (inception to February 2025) were searched for randomized controlled trials and observational studies assessing short-term cognitive outcomes in patients with NLUTD treated with anticholinergics. Study characteristics, anticholinergic type/dosage, and standardized cognitive measures were extracted. A random-effects model was used to calculate pooled effect sizes (standardized mean differences, SMDs), and heterogeneity was assessed via the Q-statistic, τ², and precision interval analysis. A total of three studies involving 139 participants (22 comparisons) met inclusion criteria. The overall pooled SMD for cognitive performance was -0.33 (95% CI: -0.72 to 0.06; P=0.10), indicating a non-significant trend toward negative cognitive effects. Subgroup analyses showed notable impairments in memory, executive function and attention, while global measures exhibited minimal change. Heterogeneity was high (Q=162.25; P<0.001), likely due to differences in patient populations, anticholinergic agents and cognitive assessments. Although short-term use of anticholinergic medications may negatively impact certain cognitive domains in patients with NLUTD, the pooled effect was not statistically significant under a random-effects model. These findings emphasize the importance of cautious agent selection and the need for further, larger-scale studies to clarify long-term cognitive safety. Future research should also assess alternative therapies, such as β3-adrenergic agonists, which have notably fewer adverse central effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.